Efesovir

Phase 2Small molecule

SScientific Center for Anti-infectious Drugs, Kazakhstan

Efesovir is one of 26 small molecule programs targeting COVID-19. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

COVID-19Not yet recruiting

COVID-19Phase 2

Not yet recruiting

Competition

Competitive Landscape

317 competitors in COVID-19

#DrugCompanyPhaseTrials

Stivarga

Bayer

Preclinical

1 2

Aimovig

Amgen

Preclinical

1 3

Aldactone

Pfizer

Preclinical

1 4

Nexavar

Bayer

Preclinical

1 5

Calciferol

Activella

Tricor

1 8

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

1 9

Benadryl

PParkedale

Preclinical

1 10

Achromycin V

WWyeth-Lederle Vaccines

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Not yet recruiting

COVID-19

NCT05060705

Clinical

Trials by Indication[1]

COVID-191 trial

"Efesovir" (FS-1) for COVID-19, Phase 2

Not yet recruiting·SScientific Center for Anti-infectious Drugs, Kazakhstan·Phase 2·NCT05060705·62 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Efesovir. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Efesovir compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Efesovir. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Scientific Center for Anti-infectious Drugs, Kazakhstan company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SScientific Center for Anti-infectious Drugs, Kazakhstan

Efesovir

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

COVID-191 trial

References

Drug Info

Quick Facts

Related News